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A report with consensus statements of the International Soci-
ety of Nephrology 2004 Consensus Workshop on Prevention of
Progression of Renal Disease, Hong Kong, June 29, 2004. This
report summarizes the discussions of the International Society
of Nephrology (ISN) 2004 Consensus Workshop on Prevention
of Progression of Renal Disease, which was held in Hong Kong
on June 29, 2004. Three key areas were discussed during the
workshop: (1) screening for chronic kidney disease; (2) eval-
uation and estimating progression of chronic kidney disease;
and (3) measures to prevent the progression of chronic kidney
disease. Fifteen consensus statements were made in these three
areas, as endorsed by the participants of the workshop. The ISN
can make use of and take reference to these statements in for-
mulating its policy for tackling chronic kidney disease, a disease
with significant global impact.
The International Society of Nephrology (ISN) 2004
Conference on Prevention of Progression of Renal Dis-
ease was held in Hong Kong from June 29–July 1, 2004,
with 1269 participants from 39 countries.
A Consensus Workshop on the Prevention of Progres-
sion of Renal Disease was held with a number of in-
ternational and Asian nephrologists gathered together
in Hong Kong (participant list shown in the Appendix).
Presidents and Chairmen of many national, regional, and
international societies of nephrology participated in the
workshop.
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Three key areas were discussed at the workshop: (1)
screening for chronic kidney disease; (2) evaluating and
estimating progression of chronic kidney disease; and (3)
measures to prevent the progression of chronic kidney
disease.
The workshop did not attempt to be comprehensive
about every facet of the prevention of progression of re-
nal disease. However, these three aspects are known to
have a significant impact on the practice of nephrologists,
as well as general physicians and primary care physicians,
in the day-to-day care of their patients. Implementa-
tion of the recommendations in these areas will help to
achieve the goal of reducing the burgeoning worldwide
epidemic of end-stage kidney disease and improving the
care of patients with renal disease.
SCREENING FOR CHRONIC KIDNEY DISEASE
Rationale for screening
In many parts of the world, end-stage renal disease
(ESRD) has a profound effect on morbidity, mortality,
and quality of life, and imposes a substantial burden on
health care expenditure [1]. This has prompted the de-
velopment of strategies aimed at preventing the devel-
opment and progression of asymptomatic chronic kidney
disease (CKD). Community strategies to reduce the inci-
dence of ESRD integrate methods of screening and early
intervention. Issues surrounding the screening of CKD
include whom to screen, how to screen, and what to do
when screening shows an abnormality.
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In view of worldwide data showing variable rates of
asymptomatic renal disease [2–7], it is worthwhile to per-
form screening programs for CKD for two reasons. First,
early detection allows the implementation of measures
to retard the progression of and even to prevent CKD.
Second, the associated complications of CKD, especially
cardiovascular morbidities, may be greatly reduced.
Whom to screen?
Population-based screening programs may not be cost-
effective in every community [8] due to variations in
genetic make-up, dietary, environmental, and economic
circumstances, as well as access to screening methods.
There have been some screening programs reported, such
as in India, which include all members of a population,
was demonstrated to be feasible and effective, and which
can be cheap depending on the methods that are applied.
The scale of screening programs, therefore, should be in-
dividualized for a particular region. Regional studies on
the cost effectiveness of population-wide versus high-risk
group screening should be carried out. We, the ISN Con-
sensus Workshop participants, recommend establishing
a global surveillance center (ISN Kidney Disease Data
Center or ISN KDDC) to coordinate worldwide stan-
dardized screening studies with standardized screening
techniques in appropriate target groups to allow for the
collection of clearly comparable data. In addition, certain
ethnic (e.g., African Americans in the United States [9],
Australian aborigines) or occupational groups (e.g., taxi
drivers in Singapore [10]) have been identified as having a
higher prevalence of “silent” CKD than the general pop-
ulation. It is important for individual regions or countries
to identify the “at-risk” groups in their population.
We recommend that patients diagnosed with diabetes
and hypertension should have regular screening for de-
velopment of kidney disease. Numerous clinical studies
demonstrate the increased likelihood of renal disease in
family members of patients with end-stage renal disease
[11, 12]. We also recommend that close relatives of pa-
tients with nephropathy caused by diabetes, hyperten-
sion, and glomerulonephritis should also be the primary
targets for screening to detect clinically silent kidney
disease.
In addition, subjects over the age of 60 to 65 years
are also at risk for unrecognized CKD [8]. There is, how-
ever, no consensus on the exact age “cut-off” for initiating
CKD screening.
How to screen?
An important area in screening for CKD is the stan-
dardization of the screening tool. The first component
is a complete survey that documents demographic data,
together with personal and family medical histories. An-
thropometric measurements should include body mass
index and blood pressure. The simplest screening test for
CKD is undoubtedly the detection of proteinuria and mi-
croscopic hematuria through standard dipstick testing.
Depending on accessibility, the actual tools for screen-
ing CKD may include standard urine dipstick test for the
detection of protein, red blood cell, specialized dipstick
test with sensitivity toward microalbuminuria, quantita-
tion of urine albumin-to-creatinine ratio, and an assay of
serum creatinine concentration for glomerular filtration
rate estimation, using accepted equations appropriate for
the region and race.
Both the American Diabetes Association and the Na-
tional Kidney Foundation support the use of standard
urinary dipsticks for screening of proteinuria, with sub-
sequent quantitation using either a spot or timed urine
collection [13, 14]. The ability of these screening tools
to detect CKD has not been systematically analyzed
for their sensitivity and specificity for predicting even-
tual ESRD. However, in a study evaluating the rela-
tionship between a single random dipstick proteinuria
and albumin-to-creatinine ratio, there was a 91% posi-
tive predictive value for ≥1+ dipstick proteinuria detect-
ing clinically significant quantitated proteinuria among
both diabetic and nondiabetic populations [15]. Further-
more, a single episode of dipstick-positive proteinuria
was found to be a significant predictor for all-cause and
cardiovascular mortality [16]. The NKF-KDOQI guide-
lines recommend that individuals be screened for CKD
using a spot urine sample for protein and an estimate of
GFR based on serum creatinine concentration [17], with a
view to risk stratification and the planning of subsequent
management steps for the degree of CKD risk. However,
it is unclear whether this combination of spot urine and
serum creatinine concentration testing is acceptable for
large-scale screening because study of the test-retest vari-
ability for serum creatinine concentrations revealed sub-
stantial variability in the same subject across laboratories
and time [18].
To date, a uniform screening strategy has not been iden-
tified. We recommend the development of standardized
region- (or nation) specific guidelines. It is envisaged that
the “tailor-made” tools for a particular region should pro-
vide reproducible and comparable results.
What to do with an abnormality?
Subjects with abnormal screening results may not nec-
essarily have unrecognized CKD. These subjects should
be referred to a nephrologist for further evaluation (dis-
cussed below). Longitudinal follow-up of these subjects
for the development or progression of CKD will provide
invaluable data on the epidemiology of renal disease.
Finally, it is important to recognize that population-
based CKD screening programs cannot be incorporated
as a component of a standard prevention strategy in
the absence of a public health policy that acknowledges
the need for screening to detect CKD and allocates
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resources for program implementation. Factors that con-
tribute to a consensus among policy makers supporting
either population-based or risk-stratified screening ap-
proaches will include cost-effectiveness analysis, clinical
trials, and resource availability in a particular country or
region.
We assert that kidney disease is already a significant
public health concern. There should be national policies
for both public health and medical professionals to ed-
ucate their societies on the importance of screening and
early detection of kidney disease on prevention.
EVALUATION AND ESTIMATING
PROGRESSION OF CHRONIC KIDNEY DISEASE
Patients with CKD should be evaluated to determine
the underlying diagnosis (i.e., type of kidney disease), the
presence of comorbid conditions, the severity of renal im-
pairment (assessed by level of kidney function), the risk
for loss of kidney function (e.g., the degree of protein-
uria), the presence of any complications related to the
level of kidney function, and other risk factors of cardio-
vascular disease [17].
Estimates of GFR are the best overall indicators of the
level of kidney function [17, 19]. Serum creatinine con-
centration alone should not be used to assess the level
of kidney function [20]. In adults, a number of equations
can be considered for the estimation of GFR, for exam-
ple, the Modification of Diet in Renal Disease (MDRD)
formula [21] or the Cockroft-Gault equation [22]. It is
recognized, however, that these equations are developed
based on North American patients, and that GFR esti-
mations based on these formulas may not be applicable
to other ethnic groups. We recommend the need for vali-
dation of these formulas based on ethnicities in different
parts of the world.
In general, measurement of 24-hour urinary creatinine
clearance is not necessary for estimation of GFR [17].
However, a 24-hour urine sample may be advisable in in-
dividuals with exceptional dietary intake (e.g., vegetarian
diet) or muscle mass (e.g., amputation, gross malnutri-
tion).
Under most circumstances, an untimed urine sample
for albumin-to-creatinine ratio (ACR) is recommended
for quantification of proteinuria in patients with CKD
[23, 24]. Follow-up monitoring of proteinuria in patients
with CKD should also be performed using similar quan-
titative measurements. We recommend the use of ACR
to quantify proteinuria and allow for follow-up. How-
ever, it is probably cost prohibitive to use ACR as a tool
for primary renal disease screening (except in diabetic
patients).
Blood pressure should be carefully measured. Other
baseline investigations recommended for CKD patients
include urine dipstick testing for red cells and leukocytes,
some form of renal imaging (usually by ultrasound), and
measurement of serum electrolytes (sodium, potassium,
chloride, and bicarbonate).
All patients with CKD should be considered to be at
high risk for the development of cardiovascular disease
[25–27]. We strongly recommend relevant screening for
the development of CKD, and recognize its close inter-
relationship with cardiovascular, diabetic, and chronic
metabolic diseases. Traditional cardiovascular disease
risk factors should be screened in all patients with CKD.
These include documentation of smoking history, mea-
surement of blood pressure, body weight, body mass in-
dex, fasting plasma glucose, fasting lipid profile, serum
uric acid level, and 12-lead electrocardiogram (ECG).
For adults with GFR <60 mL/min/1.73m2, evidence
that complications of CKD are present should be sought
[17]. Relevant tests include hemoglobin or hematocrit,
serum albumin, calcium, and phosphate levels.
Standardized blood pressure should be measured in
patients with CKD at each health encounter [17]. Pro-
teinuria should be monitored in patients with CKD us-
ing quantitative measurements. The rate of GFR decline
should be monitored in patients with CKD to assess the
effect of interventions to slow the GFR decline and pre-
dict the interval until the need for dialysis.
The rate of GFR decline should be estimated by com-
puting the GFR decline from past and ongoing measure-
ments of serum creatinine concentration [17]. With the
validation of GFR formulas in different ethnic groups, we
endorse that GFR should be estimated from serum crea-
tinine concentration at least yearly in patients with CKD.
This should be done more often in patients with GFR be-
low 60 mL/min/1.73m2, annual GFR decline greater than
4 mL/min/1.73m2, risk factors for faster progression, or
exposure to risk factors for acute GFR decline, and in
those undergoing treatment to slow progression.
MEASURES TO PREVENT THE PROGRESSION
OF CHRONIC KIDNEY DISEASE
Effective therapeutic measures are now available
which might prevent the progression of CKD. These
measures include: (1) lifestyle modification; (2) blood
pressure control; (3) glycemic control; (4) reduction of
proteinuria; (5) protein restriction; (6) lipid lowering;
(7) avoidance of nephrotoxic agents; (8) early referral
to nephrologists and (9) other measures (e.g., correction
of anemia).
Lifestyle modification
Lifestyle modification is an essential step toward
renoprotection and should be recommended to all pa-
tients with CKD [17, 27]. Patients with CKD should be
encouraged to reduce their body weight if overweight,
adopt a healthy eating habit, and restrict their dietary
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salt intake. They should also be advised to cease smok-
ing, moderate their alcohol consumption, and increase
physical activity.
Blood pressure control
All hypertensive CKD patients should be considered
for pharmacologic therapy to slow the progression of
CKD. The blood pressure goal of patients with hyperten-
sion and CKD should be less than 130/80 mm Hg [28–30].
We endorse the target for blood pressure control in CKD
patients of below 130/80 mm Hg.
Control of blood pressure takes precedence over other
considerations such as choice of antihypertensive agent.
Nevertheless, angiotensin-converting enzyme inhibitors
(ACEI) or angiotensin receptor blockers (ARB) are the
preferred antihypertensive agents, especially in patients
with proteinuria [31]. Adjunctive dietary salt restriction
is invariably required, and diuretics and multiple medica-
tions, in addition to ACE inhibitors/angiotensin receptor
blockers, may also be used to achieve the blood pres-
sure targets. Selection of additional agents [e.g., ACEI,
ARB, b-blocker, or calcium channel blockers (CCB)] to
achieve the blood pressure goal and to reduce cardiovas-
cular disease risk should also take into account patient
comorbidities (e.g., heart failure, post-myocardial infarc-
tion, high coronary disease risk, diabetes, or recurrent
stroke).
Glycemic control
Tight glycemic control in both type 1 and 2 diabetic
patients has been shown to slow the progression of mi-
croalbuminuria [32, 33]. Glycemic control in diabetic
patients with CKD should, therefore, be optimized to
achieve a target fasting plasma glucose of <7.2 mmol/L
and a HbA1c level of <7% [34, 35]. Diabetic patients
with hypertension should be treated with a systolic blood
pressure <130 mm Hg and a diastolic blood pressure of
<80 mm Hg. Hypertensive diabetics and those with mi-
croalbuminuria or macroalbuminuria, whether hyperten-
sive or not, should be treated with either an ACEI or ARB
[36–38].
Reduction of proteinuria
Proteinuria is an important independent risk factor for
the progression of CKD. Patients with CKD and protein-
uria (with and without hypertension) should be treated
with an ACEI or ARB to reduce proteinuria [39]. The
optimal level of proteinuria reduction, however, has not
been established. There is, at present, not enough data
to indicate whether combined ACEI and ARB therapy
would provide additional benefit beyond either agent
alone. We recognize that further large-scale studies to
substantiate the combined use of ACEI and ARB are
needed, but that the cost of such combined therapy may
be prohibitive for some countries.
Dietary protein restriction
Dietary protein restriction has been shown to have a
modest effect on slowing the progression of CKD [40,
41]. However, manipulation of the diet will help prevent
complications of kidney failure, such as metabolic acido-
sis, abnormalities in calcium and phosphate metabolism,
uremic symptoms, and the degree of proteinuria (dietary
protein excess raises and protein restriction lowers pro-
teinuria) [42]. These complications generally respond to
a diet with the recommended daily allowance of 0.8 g pro-
tein/kg/day. If renal function continues to deteriorate, or
proteinuria persists despite ACEI or ARB therapy, pa-
tients with CKD should be considered for additional re-
striction of dietary protein (0.6 g of protein per kg of
body weight per day). In both cases, it is important to de-
termine the actual protein intake, and patients should be
monitored by qualified dietitians to avoid losing protein
stores [43].
Lipid lowering
It remains unclear whether lipid lowering, per se, can
slow the progression of CKD. However, because patients
with CKD are at increased risk for cardiovascular dis-
ease, they should be considered to be in the “highest
risk group” for evaluation and management of hyperlipi-
demia according to established guidelines [44]. The LDL
cholesterol level of patients with CKD should be lowered
to <2.6 mmol/L (100 mg/dL).
Avoidance of nephrotoxic agents
Nephrotoxic agents, such as nonsteroidal anti-
inflammatory drugs, aminoglycosides, radiocontrast
media, and certain herbs, such as those containing aris-
tolochic acid, are detrimental to the residual renal func-
tion of patients with CKD [45, 46]. The use of these agents
should be avoided, whenever possible, in patients with
CKD [17].
Early referral to nephrologists
Early referral of CKD patients to nephrologists pro-
vides an opportunity to identify reversible causes of renal
function deterioration, and to implement renal protective
measures [47]. Patients with CKD should be referred to
a nephrologist for evaluation when their creatinine clear-
ance is less than 30 mL/min/1.73m2 [17], or earlier in pa-
tients at risk of rapid progression, or in whom doubt exists
as to their diagnosis and prognosis.
Other measures
A number of other measures have been shown to be
useful to retard the progression of CKD. These measures
include correction of anemia with erythropoietin therapy
[48], optimization of serum calcium × phosphate prod-
uct (below 4.5 mmol2/L2 or 55mg2/dL2) and parathyroid
S-6 Li et al: ISN Consensus Workshop on Prevention
Table 1. Summary of the consensus statements based on the ISN 2004 Hong Kong Consensus Workshop on Prevention of Progression of Renal
Diseases
It is recommended to establish a global surveillance center (ISN Kidney Disease Data Center or ISN KDDC) to coordinate worldwide
standardized screening studies with standardized screening techniques in appropriate target groups to allow for the collection of clearly
comparable data.
It is recommended that patients diagnosed with diabetes and hypertension should have regular screening for development of kidney disease.
It is recommended that close relatives of patients with nephropathy due to diabetes, hypertension, and glomerulonephritis should also be the
primary targets for screening to detect clinically silent kidney disease.
No consensus was made on an exact age “cut-off” for initiating CKD screening.
It is recommended to develop standardized region- (or nation-) specific guidelines. It is envisaged that the “tailor-made” tools for a particular
region should provide reproducible and comparable results.
It is asserted that kidney disease is already a significant public health concern. There should be national policies for both public health and medical
professionals to educate their societies on the importance of screening and early detection of kidney disease on prevention.
It is recommended to validate the current GFR estimation formulas based on ethnicities in different parts of the world.
It is recommended to use albumin-creatinine ratios (ACR) to quantify proteinuria and allow for follow-up. However, it is probably cost
prohibitive to use ACR as a tool for primary renal disease screening (except in diabetic patients).
It is strongly recommended to have the relevant screening for the development of CKD, recognizing its close inter-relationship with
cardiovascular, diabetic, and chronic metabolic diseases. Traditional cardiovascular disease risk factors should be screened in all patients with
CKD. These include documentation of smoking history, measurement of blood pressure, body weight, body mass index, fasting plasma glucose,
fasting lipid profile, serum uric acid level, and 12-lead electrocardiogram (ECG).
With the validation of GFR formulas in different ethnic groups, it is endorsed that GFR should be estimated from serum creatinine concentration
at least yearly in patients with CKD. This should be done more often in patients with GFR below 60 mL/min/1.73m2, annual GFR decline
greater than 4 mL/min/1.73m2, risk factors for faster progression, or exposure to risk factors for acute GFR decline, and in those undergoing
treatment to slow progression.
It is endorsed that CKD patients should be encouraged to reduce their body weight if overweight, adopt a healthy eating habit, restrict their
dietary salt intake, cease smoking, moderate their alcohol consumption, and increase physical activity.
It is endorsed to achieve the target for blood pressure control in CKD patients of below 130/80 mm Hg. It is recommended that adjunctive dietary
salt restriction is invariably required. Diuretics and multiple medications in addition to ACE inhibitors/angiotensin receptor blockers (ARB)
may also be used to achieve the blood pressure targets.
It is endorsed that glycemic control in diabetic patients with CKD should be optimized to achieve a target fasting plasma glucose of <7.2 mmol/L
and a HbA1c level of <7%. Hypertensive diabetics and those with microalbuminuria or macroalbuminuria, whether hypertensive or not,
should be treated with either an ACEI or ARB.
It is recognized that further large-scale studies to substantiate the combined use of ACEI and ARB are needed, but that the cost of such combined
therapy may be prohibitive for some countries.
It is recommended that patients with CKD should be referred to a nephrologist for evaluation when their creatinine clearance is less than
30mL/minute/1.73m2, or earlier in patients at risk of rapid progression or in whom doubt exists as to their diagnosis and prognosis.
hormone levels (2 to 3 times the upper limit of normal)
[49], maintenance of fluid balance, and attenuation of
acidosis.
CONCLUSION
The Consensus Workshop was successful in identify-
ing several aspects of renal disease screening and CKD
management upon which participants agreed. Other ar-
eas were felt to require additional research and prelimi-
nary data before firm recommendations could be made.
Table 1 summarizes the important statements that the
ISN can use and take reference to as guidelines for for-
mulating an ISN policy to tackle CKD, a disease with a
significant global impact.
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Participants of ISN 2004 Consensus Workshop on Prevention of Pro-
gression of Renal Disease, June 29, 2004, Hong Kong: Robert Atkins
(Australia), Giuseppe D’Amico (Italy), John Dirks (Canada), Barry I.
Freedman (USA), David Harris (Australia), Paul de Jong (The Nether-
lands), Priscilla Kincaid-Smith (Australia), Evan Lee (Singapore), Fu-
Keung Li (Hong Kong), Philip Kam-Tao Li (Hong Kong), Shan-Yan Lin
(China), Wai-Kei Lo (Hong Kong), Sing-Leung Lui (Hong Kong), M.K.
Mani (India), Timothy Mathew (Australia), William Mitch (USA), Mut-
sumi Murakami (Japan), Jia-Qi Qian (China), Sylvia Ramirez (Sin-
gapore), Lai-Seong Hooi (Malaysia), Sanjib Kumar Sharma (Nepal),
Cheuk-Chun Szeto (Hong Kong), Sydney Tang (Hong Kong), Yasuhiko
Tomino (Japan), Kwok-Lung Tong (Hong Kong), Wai-Kay Tsang
(Hong Kong), Kriang Tungsanga (Thailand), Haiyan Wang (China),
Jan Weening (The Netherlands), Andrew K. Wong (Hong Kong), Kim
Ming Wong (Hong Kong), Wu-Chang Yang (Taiwan), and Alex Yu
(Hong Kong).
The following participants also held an official capacity at the time
of the Workshop: Robert C. Atkins: Immediate Past President, Inter-
national Society of Nephrology; John Dirks: Chair, COMGAN, Inter-
national Society of Nephrology; David Harris: President, Australian
& New Zealand Society of Nephrology; Evan Lee: President, Singa-
pore Society of Nephrology; Philip Kam Tao Li: Chairman, Hong Kong
Society of Nephrology; Shan-Yan Lin: Immediate Past President, Chi-
nese Society of Nephrology; Wai-Kei Lo: President Elect, International
Society for Peritoneal Dialysis; William Mitch: President, American So-
ciety of Nephrology; Lai-Seong Hooi: President, Malaysian Society of
Nephrology; Kriang Tungsanga: President, Thai Society of Nephrol-
ogy; Jan Weening: President, International Society of Nephrology; Wu-
Chang Yang: President, Taiwan Society of Nephrology.
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